FDA Letter API

Nova Distributors, LLC

Letter data

Company
Nova Distributors, LLC
Recipient
Donald E. Bruch | Nova Distributors, LLC | One Nova Way | R.R. 1 Box 52 | Golden Eagle | , | IL | 62036 | United States | info@tarbarfilter.com
Issue date
2018-02-20
Posted date
Not available
FDA office
Center for Tobacco Products
Subject
Not available
Product
Tobacco
CMS ID
539670
Reference number
Not available
FEI
Not available
Inspection dates
Not available

Normalized citations

21 CFR: None found

21 U.S.C.: None found

Related FDA links

No related FDA letter link is present in the source index.

Full source text

CLOSEOUT LETTER Nova Distributors, LLC MARCS-CMS 539670 — February 20, 2018 More Warning Letters Warning Letters About Warning and Close-Out Letters Delivery Method: VIA UPS and Electronic Mail Product: Tobacco Recipient: Recipient Name Donald E. Bruch Nova Distributors, LLC One Nova Way R.R. 1 Box 52 Golden Eagle , IL 62036 United States info@tarbarfilter.com Issuing Office: Center for Tobacco Products 10903 New Hampshire Avenue Silver Spring , MD 20993 United States Dear Mr. Bruch: On November 17, 2017, the United States Food and Drug Administration's (FDA) Center for Tobacco Products (CTP) issued you a Warning Letter for the sale or distribution of modified risk tobacco products without an FDA order in effect that permits such sale or distribution, in violation of section 911 of the Federal Food, Drug, and Cosmetic Act (FD&C Act). On December 21 , 2017, you sent FDA a response to the Warning Letter, and we had a teleconference on January 17, 2018 to discuss the Warning Letter and your response. In response to the Warning Letter, you stated that you implemented corrective actions to address the violations identified in the Warning Letter. Based on our evaluation, it appears that you have taken steps to address the violations identified in the Warning Letter. This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the FD&C Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future. Should you have any questions or concerns, please contact Ele Ibarra-Pratt at (301) 796-9235 or by email at elenita.ibarrapratt@fda.hhs.gov . Sincerely, /S/ Ann Simoneau, J.D. Director Office of Compliance and Enforcement cc: Azim Chowdhury Keller and Heckman, LLP 1001 G Street, N.W. Suite 500 West Washington, D.C. 20001 chowdhury@khlaw.com Content current as of: 05/07/2019 Regulated Product(s) Tobacco